Cancer Research Cancer Epigenetics Protein Translation and Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yamamoto, Y.
Right arrow Articles by Maronpot, R. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamamoto, Y.
Right arrow Articles by Maronpot, R. R.
[Cancer Research 64, 7197-7200, October 15, 2004]
© 2004 American Association for Cancer Research

Advances in Brief

The Orphan Nuclear Receptor Constitutive Active/Androstane Receptor Is Essential for Liver Tumor Promotion by Phenobarbital in Mice

Yukio Yamamoto1, Rick Moore1, Thomas L. Goldsworthy3, Masahiko Negishi1 and Robert R. Maronpot2

Laboratories of 1 Reproductive and Developmental Toxicology and 2 Experimental Pathology, National Institute of Environmental Health Sciences, National Institutes of Health; and 3 Integrated Laboratory Systems Inc., Research Triangle Park, North Carolina


   ABSTRACT
Top
 ABSTRACT
Introduction
 Materials and Methods
 Results and Discussion
 REFERENCES
 
Hepatocellular carcinoma (HCC) is known to progress through a step often called tumor promotion. Phenobarbital (PB) is the prototype of nongenotoxic cacinogens that promote HCC in rodents. The molecular target of PB to elicit the promotion has been the subject of intense investigations over the last 30 years since it was discovered. The nuclear receptor constitutive active/androstane receptor (CAR) is activated by PB as well as by various other xenobiotics such as therapeutic drugs and environmental pollutants. CAR activation results in the transcriptional induction of numerous hepatic genes including those that encode xenobiotic-metabolizing enzymes such as a set of cytochrome P450s. In addition to PB, many CAR activators are nongenotoxic carcinogens, but the role of CAR in liver tumor promotion remains unexplored. Using Car–/– mice, we have here examined tumor promotion by chronic treatment with PB in drinking water after tumor initiation with a single dose of the genotoxic carcinogen diethylnitrosamine. None of the Car–/– mice developed either eosinophilic foci or advanced liver tumors, whereas all Car+/+ mice developed HCC and/or adenoma by 39 weeks. The results indicate that CAR is the molecular target of promotion by PB and that activation of this receptor is an essential requirement for liver tumor development.


   Introduction
Top
 ABSTRACT
 Introduction
Materials and Methods
 Results and Discussion
 REFERENCES
 
Hepatocellular carcinoma (HCC) comprises 90% of liver tumors occurring worldwide in humans, with more than half a million new cases reported every year. Diagnosis of this tumor, once restricted mostly to Asia, is now rising in Europe as well as North America (1) . Environmental factors, such as viral hepatitis and chemical exposure, are causally implicated in HCC occurrence and development of HCC is a multistage process, involving initiation, promotion and progression (2) . The molecular-based mechanism(s) underlying each stage of HCC development remains enigmatic. In rodents, HCC can be produced by initiating with genotoxic carcinogens (e.g., nitrosamines) and subsequent promotion by nongenotoxic agents such as phenobarbital (PB), 1,1,1-trichloro-2,2-bis(p-chlorophenyl)ethane, and 17{alpha}-ethynylestradiol (3, 4, 5) . Such rodent models have been used to provide insight into understanding HCC development and, in particular, the liver tumor promotion that occurs without gene mutation.

Development of eosinophilic foci and adenoma in rodents is characteristic of liver tumor promotion by agents such as PB (6) . The mutation of the ß-catenin gene, which occurs frequently in human HCC, has been observed frequently in the PB-promoted eosinophilic foci (7 , 8) . It was shown that in mice lacking the c-Jun gene, early development of liver tumors by PB was reduced (9) . In addition, knocking out genes such as Connexin32 and N-acetylglucosaminyltransferase III has also been reported to reduce the PB-induced tumor promotion in these mice (10 , 11) . Despite the apparent correlation of tumor promotion with these genes, it has not been shown that they are direct targets of PB action. Typified by the prototypic PB, nongenotoxic carcinogens generally induce hepatic xenobiotic-metabolizing enzymes such as cytochrome P450 (CYP) and certain transferases. Moreover, enzyme induction is tightly correlated with HCC development (12) , although an endogenous factor directly connecting them has not yet been identified. The nuclear receptor constitutive active/androstane receptor (CAR) was first identified as a PB-activated transcription factor that regulates the genes encoding those enzymes (13, 14, 15) . We have now used Car–/– mice to investigate the role of CAR in the development of HCC and present the experimental evidence indicating an essential role for this receptor in liver tumor promotion by PB.


   Materials and Methods
Top
 ABSTRACT
 Introduction
 Materials and Methods
Results and Discussion
 REFERENCES
 
Animals.
The original background strain of Car+/+ and Car–/– mice used in our previous work (16) was changed to a liver tumor-susceptible mouse strain by repeated backcrossing to C3H/HeNCrlBR mice (Charles River Laboratories, Wilmington, MA) until microsatellite analysis showed that mice contained 98% of the C3H markers. Mice were housed in a specific pathogen-free rodent facility, and experiments were done in accordance with National Institutes of Health guidelines for the care and use of laboratory animals. The genotypes of offspring were determined by analyzing the mutant allele using polymerase chain reaction (PCR) with genomic DNA.

Hepatocarcinogenesis Protocol and Analysis of Mice.
Tumor initiation and promotion were carried out according to a standard protocol (17) . A total of 269 male mice were given a single intraperitoneal injection of diethylnitrosamine [DEN (90 mg/kg)] at 5 weeks of age and divided into four groups (group 1, 70 Car+/+ mice; group 2, 71 Car+/+ mice; group 3, 62 Car–/– mice; and group 4, 66 Car–/– mice). The mice in groups 2 and 4 were chronically treated with PB (500 ppm) in drinking water at 7 weeks of age until they were sacrificed or moribund. Seventy-two and 79 mice were randomly selected and underwent necropsy at 30 and 39 weeks of age, respectively. The remaining 118 mice were kept for further investigations including an analysis of survival. Sera were collected, and the livers were weighed and saved for analysis. Macroscopic liver lesions were visually counted. Liver sections were stained with hematoxylin and eosin and evaluated blindly for hepatocellular proliferative lesions according to established criteria (18) . Bromodeoxyuridine (BrdUrd) was administered in the drinking water (200 ppm) for 3 days before necropsy. Immunohistochemical staining was performed on 10% formalin-fixed, paraffin-embedded sections. The mouse monoclonal anti-BrdUrd and anti-ß-catenin antibodies (Transduction Laboratories, Lexington, KY) were used, respectively. Immunoreactivity was visualized with the Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA) and 3,3'-diaminobenzidine (Dako, Carpinteria, CA). Slides were counterstained with hematoxylin.

Food and Water Consumption.
Mice received Purina Pico Chow #5058 (Ralston Purina Co., St. Louis, MO) and water ad libitum. Food consumption was measured over 7 days and calculated on a gram of feed consumed/body weight basis and showed no statistically significant difference between Car genotypes or treatments. In addition, no difference in water consumption was observed between Car+/+ and Car–/– mice, but water consumption was slightly greater in PB-treated groups.

RNA Isolation and Real-Time Polymerase Chain Reaction.
TRIzol reagent (Invitrogen, Carlsbad, CA) was used to isolate total RNA from the livers of mice treated with PB for 23 weeks. RNA was reverse transcribed by Superscript II (Invitrogen) to synthesize cDNA. Real-time PCR was carried out with an ABI Prism 7700 (Applied Biosystems, Foster City, CA), using appropriate TaqMan probe and primers 5'-6FAM-CATCACGGCCAATGTTATCTGCTCCA-TAMRA-3', 5'-ACCCCACGTTCCTCTTCCA-3', and 5'-CAGCAGGCGCAAGAACTGA-3' for CYP2B10. Assay-on-Demand Gene Expression Products (Applied Biosystems) were used as probe for NADPH-CYP reductase (Mm00435876-ml) and CYP3A11 (Mm00731567-ml). CYP2B10, CYP3A11, and reductase mRNAs were quantified by normalizing them against glyceraldehyde-3-phosphate dehydrogenase (TaqMan rodent glyceraldehyde-3-phosphate dehydrogenase control reagent; Applied Biosystems).


   Results and Discussion
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results and Discussion
REFERENCES
 
C57BL/6 mice are resistant to the development of liver tumors, and tumor occurrence is less than one-tenth that of C3H/He mice (17) . To begin our tumor study, the C57BL/6X129 background of the original Car–/– mice (16) was first changed to C3H/He by repeated backcrosses. The Car–/– C3H/He mice were viable, and newborns appeared normal and healthy. Groups of Car+/+ and Car–/– mice received injection with DEN to initiate liver tumors, and half of the mice in each group were subsequently treated with PB in drinking water. Twenty mice from each group were subjected to a pilot necropsy to examine induction of hepatic genes and assess tumor development after 23 weeks of PB treatment. First, real-time PCR was performed to evaluate the expression of known CAR target genes, Cyp2b10, Cyp3a11 and NADPH-CYP reductase (CYP Red; Fig. 1ACitation ). CYP2B10 mRNA was strongly induced in all DEN+PB-treated Car+/+ mice (>100-fold induction compared with that in the DEN-treated Car+/+ mice). No induction of the mRNA was observed in any of the DEN+PB-treated Car–/– mice. Western blots also showed the absence of CYP2B10 protein in the liver of those Car–/– mice (data not shown). CYP reductase transfers electrons from NADPH to CYP and is an essential component of the CYP-mediated monooxygenase system. CYP reductase mRNA was also induced only in the Car+/+ mice. In addition, PB treatment preferentially increased CYP3A11 mRNA in the Car+/+ mice; the average inductions were 3.0- and 1.25-fold in the Car+/+ and Car–/– mice, respectively. The results showed clearly that PB, even with chronic treatment, does not induce these genes in the absence of CAR. Proliferative liver lesions had already developed in the DEN+PB-treated Car+/+ mice by 23 weeks of PB treatment (Table 1)Citation . The DEN+PB-treated Car+/+ mice exhibited a 16-fold higher multiplicity of proliferative liver lesions than the DEN+PB-treated Car–/– mice. Liver weight as well as serum alanine aminotransferase (ALT) and alkaline phosphatase (ALP), indicative of liver damage during tumor development, also began to increase only in DEN+PB-treated Car+/+ mice (Table 1)Citation . However, in the Car–/– mice, only small putative preneoplastic foci of cellular alteration were found and no histologically diagnosed liver neoplasia was observed. At 32 weeks of PB treatment, all DEN+PB-treated Car+/+, but none of the Car–/– mice, developed advanced liver tumors (Fig. 1B)Citation . As expected, liver weight and ALT and ALP were profoundly elevated in the DEN+PB-treated Car+/+ mice at this time point, whereas such elevations were observed neither in the other treated mice (Table 1)Citation nor in the respective untreated mice (data not shown). Thorough visual analysis of the livers revealed large lesions and high multiplicity in all DEN+PB-treated Car+/+ mice (Table 1)Citation . In sharp contrast, the DEN+PB-treated Car–/– mice had approximately 15-fold fewer liver lesions that were on average less than 2 mm. The phenotypes of the lesions in these Car–/– mice were similar to those in the DEN-treated Car+/+ and Car–/– mice. Histologic analysis revealed eosinophilic adenoma, increased BrdUrd staining, and nuclear localization of ß-catenin in the DEN+PB-treated Car+/+ mice (Fig. 1C)Citation . The nuclear localization of ß-catenin is a suggested characteristic of eosinophilic liver lesions (7) . The eosinophilic adenomas were found in 19 of 20 DEN+PB-treated Car+/+ mice, but in none of the DEN+PB-treated Car–/– mice. With respect to the hepatocellular adenoma and carcinoma (Table 2)Citation , all DEN+PB-treated Car+/+ mice, but none of the DEN+PB-treated Car–/– mice, developed either or both of them; this difference was statistically significant (P < 0.001) by Fisher’s exact test. These results strikingly indicated a lack of liver tumor promotion by PB in the Car–/– mice, which was further substantiated by the survival of the mice. The DEN+PB-treated Car+/+ mice started to die at 39 weeks, and all of them died by 52 weeks of PB treatment (Fig. 2)Citation . All of the dead mice bore multiple and large liver tumors.



View larger version (70K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. Lack of advanced liver tumor in Car+/+ mice. A, induction of drug-metabolizing enzymes. Real-time PCR was performed separately to measure expression levels of CYP2B10, NADPH-CYP reductase (CYP Red), and CYP3A11 mRNAs in the liver of each mouse. Each sample was performed in triplicate. B, representative livers from mice at 32 weeks after PB promotion. The liver from a DEN+PB-treated Car+/+ mouse has multiple confluent tumors. Scale bar = 1 cm. C, histologic features of liver tumors. An eosinophilic ademoma protruding above the natural surface of the liver in a DEN+PB-treated Car+/+ mouse. The liver section was stained with hematoxylin and eosin (a). BrdUrd staining in an eosinophilic adenoma (right half of figure) compared with the normal hepatic parenchyma (b). Immunohistochemistry showing nuclear localization of ß-catenin (top of figure) in an eosinophilic adenoma (c). A hematoxylin and eosin-stained normal section from the liver of a DEN+PB-treated Car–/– mouse (d).

 

View this table:
[in this window]
[in a new window]

  		Table 1 Proliferative liver lesions, relative liver weight, and serum enzymes

 

View this table:
[in this window]
[in a new window]

  		Table 2 Incidences of proliferative liver lesions after 32 weeks of PB treatment

 


View larger version (16K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Survival curves of Car+/+ and Car–/– mice. PB treatment was continued until mice were humanely sacrificed when moribund, based on but no limited to the conditions of mice with respect to their breathing difficulty, rapid growing internal mass(es), and severe dehydration. Arrows indicate the weeks of necropsy.

 
In the absence of administration of specific promoter, DEN-initiated liver neoplasia is assumed to occur based on endogenous promotion and typically results in the development of basophilic and other noneosinophilic tumor phenotypes. Noneosinophilic adenomas were observed in the DEN-treated Car+/+ (4 of 20) and Car–/– (3 of 20) and DEN+PB-treated Car+/+ (8 of 20) mice (see "Other adenoma" in Table 2Citation ), with no significant differences in incidence. However, the DEN+PB-treated Car–/– mice did not develop adenoma of any phenotype, which was statistically different from that observed in the DEN+PB-treated Car+/+ mice (P < 0.001). Thus, PB treatment appeared to inhibit DEN-initiated tumor formation when complemented with the Car–/– genotype. A tumor-preventive effect of PB was reported previously in which DEN was injected into preweaned B6C3F1 mice, and the subsequent PB treatment decreased the number of liver tumors (19) . Whether the tumor-inhibitory effect of PB observed with the preweaned mice is mechanistically similar to that observed with the Car–/– mice remains an interesting question for future research.

Our present study provided direct evidence that CAR activation is essential in liver tumor promotion by PB. A recent DNA microarray analysis of hepatic gene expression in Car–/– mice showed that CAR up- and down-regulates more than 70 genes. In addition to the coordinated up-regulation of drug-metabolizing enzymes, CAR down-regulated genes that encode gluconeogenic enzymes, those involved in fatty acid oxidation, and proteins such as angiogenin and fibronectin (16) . Nongenotoxic carcinogens such as PB are known to stimulate cell proliferation and suppress apoptosis, leading to tumor development. Because the signaling mechanisms that regulate energy metabolism are interconnected with those controlling cell proliferation and apoptosis, the role of CAR might inadvertently extend to alter the fate of initiated cells. Our preliminary examination found that the expression of the oncogenes c-Jun and c-Myc was down-regulated and that expression of the Mdm2 gene was slightly elevated in the Car–/– mice, yet those changes displayed no obvious correlation with PB promotion (data not shown). The microarray study also revealed that more than 70 PB-modulated genes are not regulated by CAR (16) . Whereas the possibility cannot be ruled out that, in addition to CAR, another PB-regulated factor or factors may equally be required for the development of PB-promoted liver neoplasia, identifying the downstream event of CAR activation that actually leads to liver tumor development is an urgent issue of our current investigations.

In conclusion, our present study has revealed that PB promoted liver tumors only in Car+/+ mice, indicating that the nuclear receptor CAR mediates the liver tumor promotion. Once CAR-mediated pathways of tumor promotion are defined at the molecular level, the receptor can be useful as a drug target for HCC prevention.


   ACKNOWLEDGMENTS
 
We thank members of Integrated Laboratory Systems Inc. for technical assistance and members of M. Negishi’s laboratory for helpful discussion.


   FOOTNOTES
 
Grant support: Y. Yamamoto is a fellow of the Japan Society for the Promotion of Science.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Masahiko Negishi, Laboratory of Reproductive and Developmental Toxicology, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709. Phone: 919-541-2404; Fax: 919-541-0696; E-mail: negishi{at}niehs.nih.gov

Received 4/24/04. Revised 7/11/04. Accepted 7/29/04.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results and Discussion
 REFERENCES
 

  1. Llovet JM, Burroughs A, Bruix J Hepatocellular carcinoma. Lancet 2003;362:1907-17.[CrossRef][Medline]
  2. Pitot HC Altered hepatic foci: their role in murine hepatocarcinogenesis. Annu Rev Pharmacol Toxicol 1990;30:465-500.[CrossRef][Medline]
  3. Dragan YP, Pitot HC The role of the stages of initiation and promotion in phenotypic diversity during hepatocarcinogenesis in the rat. Carcinogenesis (Lond) 1992;13:739-50.[Free Full Text]
  4. Preat V, de Gerlache J, Lans M, Taper H, Roberfroid M Comparative analysis of the effect of phenobarbital, dichlorodiphenyltrichloroethane, butylated hydroxytoluene and nafenopin on rat hepatocarcinogenesis. Carcinogenesis (Lond) 1986;7:1025-8.[Abstract/Free Full Text]
  5. Mayol X, Perez-Tomas R, Cullere X, et al Cell proliferation and tumour promotion by ethinyl estradiol in rat hepatocarcinogenesis. Carcinogenesis (Lond) 1991;12:1133-6.[Abstract/Free Full Text]
  6. Evans JG, Collins MA, Savage SA, Lake BG, Butler WH The histology and development of hepatic nodules in C3H/He mice following chronic administration of phenobarbitone. Carcinogenesis (Lond) 1986;7:627-31.[Abstract/Free Full Text]
  7. Calvisi DF, Factor VM, Loi R, Thorgeirsson SS Activation of beta-catenin during hepatocarcinogenesis in transgenic mouse models: relationship to phenotype and tumor grade. Cancer Res 2001;61:2085-91.[Abstract/Free Full Text]
  8. Aydinlik H, Nguyen TD, Moennikes O, Buchmann A, Schwarz M Selective pressure during tumor promotion by phenobarbital leads to clonal outgrowth of beta-catenin-mutated mouse liver tumors. Oncogene 2001;20:7812-6.[CrossRef][Medline]
  9. Eferl R, Ricci R, Kenner L, et al Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell 2003;112:181-92.[CrossRef][Medline]
  10. Moennikes O, Buchmann A, Romualdi A, et al Lack of phenobarbital-mediated promotion of hepatocarcinogenesis in connexin32-null mice. Cancer Res 2000;60:5087-91.[Abstract/Free Full Text]
  11. Yang X, Tang J, Rogler CE, Stanley P Reduced hepatocyte proliferation is the basis of retarded liver tumor progression and liver regeneration in mice lacking N-acetylglucosaminyltransferase III. Cancer Res 2003;63:7753-9.[Abstract/Free Full Text]
  12. Diwan BA, Henneman JR, Rice JM, Nims RW Enhancement of thyroid and hepatocarcinogenesis by 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene in rats at doses that cause maximal induction of CYP2B. Carcinogenesis (Lond) 1996;17:37-43.[Abstract/Free Full Text]
  13. Honkakoski P, Zelko I, Sueyoshi T, Negishi M The nuclear orphan receptor CAR-retinoid X receptor heterodimer activates the phenobarbital-responsive enhancer module of the CYP2B gene. Mol Cell Biol 1998;18:5652-8.[Abstract/Free Full Text]
  14. Sueyoshi T, Kawamoto T, Zelko I, Honkakoski P, Negishi M The repressed nuclear receptor CAR responds to phenobarbital in activating the human CYP2B6 gene. J Biol Chem 1999;274:6043-6.[Abstract/Free Full Text]
  15. Wei P, Zhang J, Egan-Hafley M, Liang S, Moore DD The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism. Nature (Lond) 2000;407:920-3.[CrossRef][Medline]
  16. Ueda A, Hamadeh HK, Webb HK, et al Diverse roles of the nuclear orphan receptor CAR in regulating hepatic genes in response to phenobarbital. Mol Pharmacol 2002;61:1-6.[Abstract/Free Full Text]
  17. Diwan BA, Rice JM, Ohshima M, Ward JM Interstrain differences in susceptibility to liver carcinogenesis initiated by N-nitrosodiethylamine and its promotion by phenobarbital in C57BL/6NCr, C3H/HeNCrMTV- and DBA/2NCr mice. Carcinogenesis (Lond) 1986;7:215-20.[Abstract/Free Full Text]
  18. Harada T, Enomoto A, Boorman GA, Maronpot RR Liver and gallbladder Maronpot RR eds. . Pathology of the mouse 1999p. 119-83. Cache River Press Vienna
  19. Lee GH, Ooasa T, Osanai M Mechanism of the paradoxical, inhibitory effect of phenobarbital on hepatocarcinogenesis initiated in infant B6C3F1 mice with diethylnitrosamine. Cancer Res 1998;58:1665-9.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Toxicol SciHome page
A. K. Goetz and D. J. Dix
Mode of Action for Reproductive and Hepatic Toxicity Inferred from a Genomic Study of Triazole Antifungals
Toxicol. Sci., August 1, 2009; 110(2): 449 - 462.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
J. M. Phillips, L. D. Burgoon, and J. I. Goodman
The Constitutive Active/Androstane Receptor Facilitates Unique Phenobarbital-Induced Expression Changes of Genes Involved in Key Pathways in Precancerous Liver and Liver Tumors
Toxicol. Sci., August 1, 2009; 110(2): 319 - 333.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
S. Nesnow, W. Ward, T. Moore, H. Ren, and S. D. Hester
Discrimination of Tumorigenic Triazole Conazoles from Phenobarbital by Transcriptional Analyses of Mouse Liver Gene Expression
Toxicol. Sci., July 1, 2009; 110(1): 68 - 83.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
J. M. Phillips, L. D. Burgoon, and J. I. Goodman
Phenobarbital Elicits Unique, Early Changes in the Expression of Hepatic Genes that Affect Critical Pathways in Tumor-Prone B6C3F1 Mice
Toxicol. Sci., June 1, 2009; 109(2): 193 - 205.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
H. Li, T. Chen, J. Cottrell, and H. Wang
Nuclear Translocation of Adenoviral-Enhanced Yellow Fluorescent Protein-Tagged-Human Constitutive Androstane Receptor (hCAR): A Novel Tool for Screening hCAR Activators in Human Primary Hepatocytes
Drug Metab. Dispos., May 1, 2009; 37(5): 1098 - 1106.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
J. M. Phillips and J. I. Goodman
Multiple Genes Exhibit Phenobarbital-Induced Constitutive Active/Androstane Receptor-Mediated DNA Methylation Changes during Liver Tumorigenesis and in Liver Tumors
Toxicol. Sci., April 1, 2009; 108(2): 273 - 289.
[Abstract] [Full Text] [PDF]

Home page
 MutagenesisHome page
J. A. Ross, T. Moore, and S. A. Leavitt
In vivo mutagenicity of conazole fungicides correlates with tumorigenicity
Mutagenesis, March 1, 2009; 24(2): 149 - 152.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
Y. Deguchi, T. Yamada, Y. Hirose, H. Nagahori, M. Kushida, K. Sumida, T. Sukata, Y. Tomigahara, K. Nishioka, S. Uwagawa, et al.
Mode of Action Analysis for the Synthetic Pyrethroid Metofluthrin-Induced Rat Liver Tumors: Evidence for Hepatic CYP2B Induction and Hepatocyte Proliferation
Toxicol. Sci., March 1, 2009; 108(1): 69 - 80.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
T. Yamada, S. Uwagawa, Y. Okuno, S. M. Cohen, and H. Kaneko
Case Study: An Evaluation of the Human Relevance of the Synthetic Pyrethroid Metofluthrin-Induced Liver Tumors in Rats Based on Mode of Action
Toxicol. Sci., March 1, 2009; 108(1): 59 - 68.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
S. Surapureddi, R. Rana, J. K. Reddy, and J. A. Goldstein
Nuclear Receptor Coactivator 6 Mediates the Synergistic Activation of Human Cytochrome P-450 2C9 by the Constitutive Androstane Receptor and Hepatic Nuclear Factor-4{alpha}
Mol. Pharmacol., September 1, 2008; 74(3): 913 - 923.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
L. Li, T. Chen, J. D. Stanton, T. Sueyoshi, M. Negishi, and H. Wang
The Peripheral Benzodiazepine Receptor Ligand 1-(2-Chlorophenyl-methylpropyl)-3-isoquinoline-carboxamide Is a Novel Antagonist of Human Constitutive Androstane Receptor
Mol. Pharmacol., August 1, 2008; 74(2): 443 - 453.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
Y. Yamamoto and M. Negishi
The Antiapoptotic Factor Growth Arrest and DNA-Damage-Inducible 45 {beta} Regulates the Nuclear Receptor Constitutive Active/Androstane Receptor-Mediated Transcription
Drug Metab. Dispos., July 1, 2008; 36(7): 1189 - 1193.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
J. M. Phillips and J. I. Goodman
Identification of Genes that May Play Critical Roles in Phenobarbital (PB)-Induced Liver Tumorigenesis due to Altered DNA Methylation
Toxicol. Sci., July 1, 2008; 104(1): 86 - 99.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
M. B. Rosen, J. S. Lee, H. Ren, B. Vallanat, J. Liu, M. P. Waalkes, B. D. Abbott, C. Lau, and J. C. Corton
Toxicogenomic Dissection of the Perfluorooctanoic Acid Transcript Profile in Mouse Liver: Evidence for the Involvement of Nuclear Receptors PPAR{alpha} and CAR
Toxicol. Sci., May 1, 2008; 103(1): 46 - 56.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
T. Sueyoshi, R. Moore, J. Sugatani, Y. Matsumura, and M. Negishi
PPP1R16A, The Membrane Subunit of Protein Phosphatase 1{beta}, Signals Nuclear Translocation of the Nuclear Receptor Constitutive Active/Androstane Receptor
Mol. Pharmacol., April 1, 2008; 73(4): 1113 - 1121.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
N. Kiyosawa, J. C. Kwekel, L. D. Burgoon, K. J. Williams, C. Tashiro, B. Chittim, and T. R. Zacharewski
o,p'-DDT Elicits PXR/CAR-, Not ER-, Mediated Responses in the Immature Ovariectomized Rat Liver
Toxicol. Sci., February 1, 2008; 101(2): 350 - 363.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
R. C. Peffer, J. G. Moggs, T. Pastoor, R. A. Currie, J. Wright, G. Milburn, F. Waechter, and I. Rusyn
Mouse Liver Effects of Cyproconazole, a Triazole Fungicide: Role of the Constitutive Androstane Receptor
Toxicol. Sci., September 1, 2007; 99(1): 315 - 325.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
C. G. Woods, J. P. Vanden Heuvel, and I. Rusyn
Genomic Profiling in Nuclear Receptor-Mediated Toxicity
Toxicol Pathol, June 1, 2007; 35(4): 474 - 494.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
M. T. Martin, R. J. Brennan, W. Hu, E. Ayanoglu, C. Lau, H. Ren, C. R. Wood, J. C. Corton, R. J. Kavlock, and D. J. Dix
Toxicogenomic Study of Triazole Fungicides and Perfluoroalkyl Acids in Rat Livers Predicts Toxicity and Categorizes Chemicals Based on Mechanisms of Toxicity
Toxicol. Sci., June 1, 2007; 97(2): 595 - 613.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
C. Koike, R. Moore, and M. Negishi
Extracellular Signal-Regulated Kinase Is an Endogenous Signal Retaining the Nuclear Constitutive Active/Androstane Receptor (CAR) in the Cytoplasm of Mouse Primary Hepatocytes
Mol. Pharmacol., May 1, 2007; 71(5): 1217 - 1221.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
Y. Yamazaki, S. Kakizaki, N. Horiguchi, N. Sohara, K. Sato, H. Takagi, M. Mori, and M. Negishi
The role of the nuclear receptor constitutive androstane receptor in the pathogenesis of non-alcoholic steatohepatitis
Gut, April 1, 2007; 56(4): 565 - 574.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
J. M. Phillips, Y. Yamamoto, M. Negishi, R. R. Maronpot, and J. I. Goodman
Orphan Nuclear Receptor Constitutive Active/Androstane Receptor-Mediated Alterations in DNA Methylation during Phenobarbital Promotion of Liver Tumorigenesis
Toxicol. Sci., March 1, 2007; 96(1): 72 - 82.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. S. Tien, K. Matsui, R. Moore, and M. Negishi
The Nuclear Receptor Constitutively Active/Androstane Receptor Regulates Type 1 Deiodinase and Thyroid Hormone Activity in the Regenerating Mouse Liver
J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 307 - 313.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
D. M. Nelson, V. Bhaskaran, W. R. Foster, and L. D. Lehman-McKeeman
p53-Independent Induction of Rat Hepatic Mdm2 following Administration of Phenobarbital and Pregnenolone 16{alpha}-Carbonitrile
Toxicol. Sci., December 1, 2006; 94(2): 272 - 280.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
J. Strathmann, M. Schwarz, J. C. Tharappel, H. P. Glauert, B. T. Spear, L. W. Robertson, K. E. Appel, and A. Buchmann
PCB 153, a Non-dioxin-like Tumor Promoter, Selects for {beta}-Catenin (Catnb)-Mutated Mouse Liver Tumors
Toxicol. Sci., September 1, 2006; 93(1): 34 - 40.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
F. Hosseinpour, R. Moore, M. Negishi, and T. Sueyoshi
Serine 202 Regulates the Nuclear Translocation of Constitutive Active/Androstane Receptor
Mol. Pharmacol., April 1, 2006; 69(4): 1095 - 1102.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
M. P. Holsapple, H. C. Pitot, S. H. Cohen, A. R. Boobis, J. E. Klaunig, T. Pastoor, V. L. Dellarco, and Y. P. Dragan
Mode of Action in Relevance of Rodent Liver Tumors to Human Cancer Risk
Toxicol. Sci., January 1, 2006; 89(1): 51 - 56.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
W. Huang, J. Zhang, M. Washington, J. Liu, J. M. Parant, G. Lozano, and D. D. Moore
Xenobiotic Stress Induces Hepatomegaly and Liver Tumors via the Nuclear Receptor Constitutive Androstane Receptor
Mol. Endocrinol., June 1, 2005; 19(6): 1646 - 1653.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yamamoto, Y.
Right arrow Articles by Maronpot, R. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamamoto, Y.
Right arrow Articles by Maronpot, R. R.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online